278 related articles for article (PubMed ID: 26606875)
1. Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism.
Karashima S; Yoneda T; Kometani M; Ohe M; Mori S; Sawamura T; Furukawa K; Seta T; Yamagishi M; Takeda Y
Hypertens Res; 2016 Mar; 39(3):133-7. PubMed ID: 26606875
[TBL] [Abstract][Full Text] [Related]
2. Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y; Yoshimoto T; Fukuda T; Murakami M; Bouchi R; Minami I; Hashimoto K; Fujii Y; Kihara K; Ogawa Y
Intern Med; 2018 Sep; 57(17):2459-2466. PubMed ID: 29709927
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.
Fourkiotis V; Vonend O; Diederich S; Fischer E; Lang K; Endres S; Beuschlein F; Willenberg HS; Rump LC; Allolio B; Reincke M; Quinkler M;
Eur J Endocrinol; 2013 Jan; 168(1):75-81. PubMed ID: 23033260
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
5. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
Colussi G; Catena C; Sechi LA
J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
[TBL] [Abstract][Full Text] [Related]
7. Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Matsuda Y; Kawate H; Matsuzaki C; Sakamoto R; Shibue K; Ohnaka K; Anzai K; Nomura M; Takayanagi R
Endocr J; 2016; 63(3):249-55. PubMed ID: 26727302
[TBL] [Abstract][Full Text] [Related]
8. A possible association between primary aldosteronism and a lower beta-cell function.
Mosso LM; Carvajal CA; Maiz A; Ortiz EH; Castillo CR; Artigas RA; Fardella CE
J Hypertens; 2007 Oct; 25(10):2125-30. PubMed ID: 17885557
[TBL] [Abstract][Full Text] [Related]
9. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
[TBL] [Abstract][Full Text] [Related]
10. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
11. Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist.
Sato A; Fukuda S
Hypertens Res; 2013 Oct; 36(10):879-84. PubMed ID: 23864056
[TBL] [Abstract][Full Text] [Related]
12. Changes in Glucose Metabolism after Adrenalectomy or Treatment with a Mineralocorticoid Receptor Antagonist for Primary Aldosteronism.
Lin YF; Peng KY; Chang CH; Hu YH; Wu VC; Chung SD;
Endocrinol Metab (Seoul); 2020 Dec; 35(4):838-846. PubMed ID: 33261310
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome.
Homma T; Fujisawa M; Arai K; Ishii M; Sada T; Ikeda M
J Vet Med Sci; 2012 Aug; 74(8):1015-22. PubMed ID: 22498927
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats.
Nielsen FT; Jensen BL; Marcussen N; Skøtt O; Bie P
Nephrol Dial Transplant; 2008 Sep; 23(9):2777-83. PubMed ID: 18424460
[TBL] [Abstract][Full Text] [Related]
15. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
16. Effect of spironolactone on fluid volumes and adrenal steroids in primary aldosteronism.
Ichikawa S; Tajima Y; Sakamaki T; Matsuo H; Kogure M; Hirano Y; Yagi S; Murata K
Jpn Circ J; 1984 Nov; 48(11):1184-96. PubMed ID: 6502914
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
18. Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
Yoneda T; Demura M; Takata H; Kometani M; Karashima S; Yamagishi M; Takeda Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1109-13. PubMed ID: 22337911
[TBL] [Abstract][Full Text] [Related]
19. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonists and endothelial function.
Maron BA; Leopold JA
Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
